Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units | 22 | 2022 | 743 | 1.370 |
Why?
|
| Critical Illness | 18 | 2020 | 743 | 1.150 |
Why?
|
| Cancer Care Facilities | 8 | 2022 | 908 | 0.830 |
Why?
|
| Critical Care | 11 | 2022 | 810 | 0.610 |
Why?
|
| Terminal Care | 5 | 2019 | 465 | 0.560 |
Why?
|
| Neoplasms | 28 | 2022 | 15930 | 0.550 |
Why?
|
| Respiration, Artificial | 3 | 2012 | 583 | 0.480 |
Why?
|
| Advance Directives | 3 | 2010 | 90 | 0.440 |
Why?
|
| Hospital Mortality | 12 | 2022 | 1317 | 0.420 |
Why?
|
| Sepsis | 3 | 2022 | 689 | 0.370 |
Why?
|
| Shock, Septic | 2 | 2022 | 187 | 0.350 |
Why?
|
| Professional-Family Relations | 2 | 2022 | 130 | 0.280 |
Why?
|
| Thrombophilia | 1 | 2007 | 56 | 0.270 |
Why?
|
| Acute Kidney Injury | 2 | 2011 | 784 | 0.250 |
Why?
|
| Multiple Organ Failure | 3 | 2012 | 177 | 0.240 |
Why?
|
| Craniotomy | 1 | 2007 | 304 | 0.240 |
Why?
|
| Life Support Care | 2 | 2001 | 53 | 0.240 |
Why?
|
| Respiratory Insufficiency | 2 | 2017 | 348 | 0.240 |
Why?
|
| Pain Management | 2 | 2020 | 715 | 0.230 |
Why?
|
| Leukemia | 1 | 2012 | 1721 | 0.220 |
Why?
|
| Length of Stay | 7 | 2017 | 2015 | 0.210 |
Why?
|
| Decision Making | 4 | 2015 | 1247 | 0.210 |
Why?
|
| Comprehensive Health Care | 1 | 2022 | 48 | 0.200 |
Why?
|
| Renal Dialysis | 1 | 2009 | 931 | 0.200 |
Why?
|
| Patient Admission | 3 | 2019 | 236 | 0.200 |
Why?
|
| Middle Aged | 39 | 2022 | 90460 | 0.190 |
Why?
|
| Cardiopulmonary Resuscitation | 4 | 2016 | 338 | 0.190 |
Why?
|
| Palliative Care | 4 | 2019 | 2161 | 0.190 |
Why?
|
| Logistic Models | 9 | 2012 | 3469 | 0.190 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 4400 | 0.170 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 78 | 0.170 |
Why?
|
| Organ Dysfunction Scores | 3 | 2016 | 70 | 0.170 |
Why?
|
| Heart Arrest | 3 | 2016 | 380 | 0.170 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 321 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 2430 | 0.160 |
Why?
|
| Adult | 31 | 2022 | 81933 | 0.160 |
Why?
|
| Referral and Consultation | 2 | 2016 | 941 | 0.160 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2019 | 92 | 0.160 |
Why?
|
| Advance Care Planning | 1 | 2019 | 93 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2017 | 6987 | 0.150 |
Why?
|
| Male | 36 | 2022 | 129088 | 0.140 |
Why?
|
| Triage | 1 | 2019 | 258 | 0.140 |
Why?
|
| Positive-Pressure Respiration | 1 | 2017 | 124 | 0.140 |
Why?
|
| Noninvasive Ventilation | 1 | 2017 | 40 | 0.130 |
Why?
|
| Aged | 24 | 2020 | 73517 | 0.130 |
Why?
|
| Attitude of Health Personnel | 2 | 2019 | 920 | 0.130 |
Why?
|
| Female | 34 | 2022 | 149288 | 0.130 |
Why?
|
| Resuscitation Orders | 3 | 2011 | 69 | 0.120 |
Why?
|
| Aminocaproic Acid | 1 | 2014 | 17 | 0.120 |
Why?
|
| Burnout, Professional | 1 | 2019 | 227 | 0.120 |
Why?
|
| Blood Transfusion | 1 | 1998 | 583 | 0.120 |
Why?
|
| Humans | 45 | 2022 | 272087 | 0.120 |
Why?
|
| Texas | 8 | 2017 | 6440 | 0.120 |
Why?
|
| Multivariate Analysis | 6 | 2013 | 4352 | 0.120 |
Why?
|
| Withholding Treatment | 2 | 2019 | 155 | 0.120 |
Why?
|
| Thrombolytic Therapy | 1 | 2016 | 258 | 0.110 |
Why?
|
| Aged, 80 and over | 15 | 2017 | 31066 | 0.110 |
Why?
|
| Pulmonary Alveoli | 1 | 2014 | 223 | 0.110 |
Why?
|
| Steroids | 1 | 2014 | 375 | 0.110 |
Why?
|
| Prospective Studies | 10 | 2019 | 13410 | 0.110 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 1950 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 1 | 1998 | 1772 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 343 | 0.100 |
Why?
|
| Italy | 1 | 2012 | 189 | 0.100 |
Why?
|
| Leukemia, Myeloid | 1 | 2017 | 994 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2017 | 711 | 0.100 |
Why?
|
| Lung Diseases | 2 | 2014 | 755 | 0.100 |
Why?
|
| Creatinine | 2 | 2011 | 546 | 0.100 |
Why?
|
| Electronic Health Records | 1 | 2019 | 971 | 0.100 |
Why?
|
| Retrospective Studies | 16 | 2022 | 39831 | 0.090 |
Why?
|
| Prognosis | 9 | 2022 | 22555 | 0.090 |
Why?
|
| Blood Gas Analysis | 1 | 2010 | 106 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2014 | 747 | 0.090 |
Why?
|
| Leukocytosis | 1 | 2010 | 115 | 0.090 |
Why?
|
| Forecasting | 1 | 2012 | 706 | 0.090 |
Why?
|
| Inpatients | 2 | 2013 | 697 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 4994 | 0.080 |
Why?
|
| Survival Analysis | 5 | 2017 | 9326 | 0.080 |
Why?
|
| Blood Urea Nitrogen | 1 | 2009 | 101 | 0.080 |
Why?
|
| Hospital Costs | 1 | 2011 | 251 | 0.080 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2009 | 622 | 0.080 |
Why?
|
| Creatine | 1 | 2009 | 60 | 0.080 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2009 | 139 | 0.080 |
Why?
|
| Serum Albumin | 1 | 2009 | 246 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2011 | 622 | 0.080 |
Why?
|
| Models, Statistical | 2 | 2012 | 1190 | 0.070 |
Why?
|
| Point-of-Care Systems | 1 | 2010 | 215 | 0.070 |
Why?
|
| Young Adult | 7 | 2017 | 22142 | 0.070 |
Why?
|
| Hypoxia | 1 | 2010 | 477 | 0.070 |
Why?
|
| Area Under Curve | 3 | 2017 | 729 | 0.070 |
Why?
|
| Urethane | 1 | 2006 | 15 | 0.070 |
Why?
|
| Pentobarbital | 1 | 2006 | 28 | 0.070 |
Why?
|
| Blood Coagulation Tests | 1 | 2007 | 83 | 0.070 |
Why?
|
| Isoflurane | 1 | 2006 | 72 | 0.070 |
Why?
|
| Transplantation, Homologous | 3 | 2017 | 3036 | 0.060 |
Why?
|
| Dyspnea | 2 | 2000 | 421 | 0.060 |
Why?
|
| Time Factors | 5 | 2017 | 13139 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 6270 | 0.060 |
Why?
|
| Acute Disease | 3 | 2017 | 2517 | 0.060 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2003 | 62 | 0.050 |
Why?
|
| Anemia | 1 | 2009 | 730 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2009 | 1603 | 0.050 |
Why?
|
| Risk Factors | 5 | 2017 | 18051 | 0.050 |
Why?
|
| Bacterial Infections | 2 | 1998 | 507 | 0.050 |
Why?
|
| Drug Resistance, Multiple | 1 | 2003 | 221 | 0.050 |
Why?
|
| Cohort Studies | 4 | 2017 | 9500 | 0.050 |
Why?
|
| Myeloproliferative Disorders | 1 | 2010 | 881 | 0.050 |
Why?
|
| Rifampin | 1 | 2003 | 220 | 0.050 |
Why?
|
| Matched-Pair Analysis | 1 | 2001 | 101 | 0.050 |
Why?
|
| Minocycline | 1 | 2003 | 189 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2010 | 1589 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2007 | 2867 | 0.050 |
Why?
|
| Oxygen Consumption | 2 | 2010 | 423 | 0.050 |
Why?
|
| Ethics, Clinical | 1 | 2001 | 83 | 0.050 |
Why?
|
| Netherlands | 1 | 2020 | 89 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2003 | 383 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2017 | 33909 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 5118 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2022 | 312 | 0.050 |
Why?
|
| Catheterization, Central Venous | 1 | 2003 | 366 | 0.040 |
Why?
|
| Contraindications, Drug | 1 | 2019 | 4 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2000 | 220 | 0.040 |
Why?
|
| Neuromuscular Blockade | 1 | 2019 | 15 | 0.040 |
Why?
|
| Ecuador | 1 | 2019 | 15 | 0.040 |
Why?
|
| Argentina | 1 | 2019 | 74 | 0.040 |
Why?
|
| Chile | 1 | 2019 | 68 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 996 | 0.040 |
Why?
|
| Spain | 1 | 2019 | 101 | 0.040 |
Why?
|
| Death | 1 | 2020 | 125 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 441 | 0.040 |
Why?
|
| Medical Audit | 2 | 2010 | 198 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2007 | 2259 | 0.040 |
Why?
|
| Decision Trees | 1 | 2019 | 180 | 0.040 |
Why?
|
| Chi-Square Distribution | 3 | 2010 | 1327 | 0.040 |
Why?
|
| Cross Infection | 1 | 2003 | 548 | 0.040 |
Why?
|
| Age Distribution | 1 | 2000 | 730 | 0.040 |
Why?
|
| Incidence | 3 | 2017 | 5864 | 0.040 |
Why?
|
| Family | 1 | 2022 | 779 | 0.040 |
Why?
|
| Benzodiazepines | 1 | 2019 | 181 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 220 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 2369 | 0.040 |
Why?
|
| Biomarkers | 1 | 2009 | 5115 | 0.040 |
Why?
|
| Workload | 1 | 2019 | 200 | 0.040 |
Why?
|
| Kidney | 1 | 2006 | 2266 | 0.040 |
Why?
|
| ROC Curve | 3 | 2010 | 1248 | 0.040 |
Why?
|
| Bilirubin | 1 | 1998 | 224 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 1116 | 0.040 |
Why?
|
| Survival Rate | 4 | 2013 | 12534 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2009 | 6885 | 0.030 |
Why?
|
| Probability | 1 | 1998 | 887 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 364 | 0.030 |
Why?
|
| Respiration | 1 | 1998 | 465 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1998 | 349 | 0.030 |
Why?
|
| Patient Transfer | 1 | 2016 | 138 | 0.030 |
Why?
|
| Patient Participation | 1 | 2019 | 452 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2019 | 1017 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2022 | 918 | 0.030 |
Why?
|
| Adolescent | 6 | 2011 | 32730 | 0.030 |
Why?
|
| Heart Rate | 1 | 1998 | 761 | 0.030 |
Why?
|
| Comorbidity | 2 | 2013 | 2439 | 0.030 |
Why?
|
| Dobutamine | 1 | 1994 | 60 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 1995 | 329 | 0.030 |
Why?
|
| Hepatitis, Chronic | 1 | 2013 | 14 | 0.030 |
Why?
|
| Gastric Mucosa | 2 | 1995 | 659 | 0.030 |
Why?
|
| Hospitals | 1 | 2017 | 493 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2017 | 650 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 1998 | 458 | 0.030 |
Why?
|
| Prevalence | 2 | 2013 | 3427 | 0.030 |
Why?
|
| Hypotension | 1 | 1995 | 237 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 1998 | 2048 | 0.030 |
Why?
|
| Communication | 1 | 2019 | 858 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 1995 | 593 | 0.030 |
Why?
|
| Anxiety | 1 | 2019 | 1230 | 0.030 |
Why?
|
| Hospitalization | 2 | 1999 | 2203 | 0.030 |
Why?
|
| Apoptosis | 1 | 2006 | 7837 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2001 | 6236 | 0.020 |
Why?
|
| Arginine | 1 | 1995 | 510 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2017 | 2335 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 15279 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1995 | 891 | 0.020 |
Why?
|
| Colon | 1 | 1995 | 691 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 1995 | 666 | 0.020 |
Why?
|
| Pain | 1 | 2019 | 1697 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 2058 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1324 | 0.020 |
Why?
|
| Echocardiography | 1 | 2016 | 1241 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 1459 | 0.020 |
Why?
|
| Calcium | 1 | 1995 | 1594 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2006 | 12223 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2009 | 485 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2009 | 485 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 2253 | 0.020 |
Why?
|
| DNA Fragmentation | 1 | 2006 | 208 | 0.020 |
Why?
|
| Linear Models | 1 | 2009 | 1102 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 946 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2006 | 380 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 2359 | 0.020 |
Why?
|
| Algorithms | 2 | 2010 | 3925 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 1076 | 0.010 |
Why?
|
| DNA Primers | 1 | 2006 | 1513 | 0.010 |
Why?
|
| Vancomycin Resistance | 1 | 2003 | 60 | 0.010 |
Why?
|
| Enterococcus | 1 | 2003 | 61 | 0.010 |
Why?
|
| Rats | 2 | 2006 | 6640 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1995 | 2417 | 0.010 |
Why?
|
| Software | 1 | 2010 | 1387 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 5001 | 0.010 |
Why?
|
| Opportunistic Infections | 1 | 2003 | 237 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2006 | 2256 | 0.010 |
Why?
|
| Medical Futility | 1 | 2001 | 56 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 2496 | 0.010 |
Why?
|
| Cause of Death | 1 | 2003 | 787 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 3651 | 0.010 |
Why?
|
| Bacteremia | 1 | 2003 | 722 | 0.010 |
Why?
|
| Quality of Life | 1 | 2011 | 4755 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2002 | 700 | 0.010 |
Why?
|
| Managed Care Programs | 1 | 1996 | 84 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2000 | 809 | 0.010 |
Why?
|
| Narcotics | 1 | 1996 | 128 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1996 | 141 | 0.010 |
Why?
|
| Terminally Ill | 1 | 1996 | 96 | 0.010 |
Why?
|
| omega-N-Methylarginine | 1 | 1995 | 34 | 0.010 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1996 | 131 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1995 | 76 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1995 | 262 | 0.010 |
Why?
|
| Health Resources | 1 | 1996 | 173 | 0.010 |
Why?
|
| Chelating Agents | 1 | 1995 | 130 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1995 | 596 | 0.010 |
Why?
|
| Lactates | 1 | 1994 | 123 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 1998 | 690 | 0.010 |
Why?
|
| Child | 2 | 2003 | 30559 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1995 | 973 | 0.010 |
Why?
|
| Oxygen | 1 | 1994 | 800 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1995 | 1125 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1995 | 3543 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 1996 | 1243 | 0.000 |
Why?
|
| Animals | 2 | 2006 | 62822 | 0.000 |
Why?
|
| Child, Preschool | 1 | 2003 | 17056 | 0.000 |
Why?
|
| United States | 1 | 2003 | 16066 | 0.000 |
Why?
|
| Disease Progression | 1 | 1996 | 6911 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1996 | 3176 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1996 | 12012 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1996 | 16244 | 0.000 |
Why?
|